Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study

Bone Marrow Transplantation volume 58, pages 1163–1166 (2023)Cite this article

Subjects

Access through your institution
Buy or subscribe

T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are rare diseases in adults with a poor prognosis [1,2,3]. Disease relapse is the main cause of transplantation failure and patients with T-ALL have frustrating outcomes relative to those with B-ALL mainly due to a dearth of effective salvage therapies [4,5,6,7]. Exploring innovative approaches to prevent relapse after allo-HSCT in T-ALL/LBL is an urgent need considering the difficulties to treat post-transplant relapse. Furthermore, maintenance therapy for T-ALL/T-LBL after HSCT has been rarely reported.

Chidamide is an orally active and a new subtype-selective HDACi [8]. As a single agent or in combination therapies, chidamide had potent antitumor activity in vitro and in mouse models [9]. Recently, a study reported that chidamide combined with chemotherapy could have a better progress-free survival (PFS) compared to the chemotherapy-alone group in refractory or relapsed T-ALL/T-LBL patients [10]. In clinical trials, chidamide also has shown good tolerability and safety [10, 11]. This provides a solid basis for maintenance therapy with chidamide in T-ALL/T-LBL patients.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The probability of OS, CIR, and EFSMRD according to chidamide maintenance therapy.

Data availability

The original contributions presented in the study were included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

References

  1. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012;119:34–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Haydu JE, Ferrando AA. Early T-cell precursor acute lymphoblastic leukaemia. Curr Opin Hematol. 2013;20:369–73.

    Article  CAS  PubMed  Google Scholar 

  4. Ishida H, Kato M, Kawahara Y, Ishimaru S, Najima Y, Kako S, et al. Prognostic factors of children and adolescents with T-cell acute lymphoblastic leukemia after allogeneic transplantation. Hematol Oncol. 2022;40:457–68.

    Article  PubMed  Google Scholar 

  5. Yasuda S, Najima Y, Konishi T, Yamada Y, Nagata A, Takezaki T, et al. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. Leuk Res. 2021;108:106627.

    Article  CAS  PubMed  Google Scholar 

  6. Meng T, Qi J, Zhu Y, Xu Y, Chen F, Xue S, et al. Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia. Hematol Oncol. 2021;39:358–63.

    Article  CAS  PubMed  Google Scholar 

  7. Diorio C, Teachey DT. Harnessing immunotherapy for pediatric T-cell malignancies. Expert Rev Clin Immunol. 2020;16:361–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Suresh PS, Devaraj VC, Srinivas NR, Mullangi R. Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine. Biomed Chromatogr, 2017;31:e3807.

  9. Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharm. 2012;69:901–9.

    Article  CAS  Google Scholar 

  10. Guan W, Jing Y, Dou L, Wang M, Xiao Y, Yu L. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia. Leuk Lymphoma. 2020;61:855–61.

    Article  CAS  PubMed  Google Scholar 

  11. Guo W, Wang X, Li J, Yin X, Zhao Y, Tang Y, et al. Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China. Front Oncol. 2022;12:875469.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The study was supported by the Haihe Laboratory of Cell Ecosystem Innovation Fund (No. 22HHXBSS00034), the National Natural Science Foundation of China (No. 82100225, No. 82170217 and No. 82070192), Tianjin Health Science and Technology Project (No. TJWJ2022MS001), CAMS Innovation Fund for Medical Sciences (No. 2021-I2M-1-073), and Key Project of Tianjin Natural Science Foundation (No. 20JCZDJC00410).

Author information

Author notes

  1. These authors contributed equally: Wenwen Guo, Yigeng Cao.

Authors and Affiliations

  1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China

    Wenwen Guo, Yigeng Cao, Jia Liu, Xinhui Zheng, Mingyang Wang, Yawei Zheng, Xiaoyu Zhang, Weihua Zhai, Xin Chen, Rongli Zhang, Qiaoling Ma, Donglin Yang, Jialin Wei, Yi He, Aiming Pang, Sizhou Feng, Mingzhe Han & Erlie Jiang

  2. Tianjin Institutes of Health Science, Tianjin, 301600, China

    Wenwen Guo, Yigeng Cao, Jia Liu, Xinhui Zheng, Mingyang Wang, Yawei Zheng, Xiaoyu Zhang, Weihua Zhai, Xin Chen, Rongli Zhang, Qiaoling Ma, Donglin Yang, Jialin Wei, Yi He, Aiming Pang, Sizhou Feng, Mingzhe Han & Erlie Jiang

Authors
  1. Wenwen Guo
    View author publications

    Search author on:PubMed Google Scholar

  2. Yigeng Cao
    View author publications

    Search author on:PubMed Google Scholar

  3. Jia Liu
    View author publications

    Search author on:PubMed Google Scholar

  4. Xinhui Zheng
    View author publications

    Search author on:PubMed Google Scholar

  5. Mingyang Wang
    View author publications

    Search author on:PubMed Google Scholar

  6. Yawei Zheng
    View author publications

    Search author on:PubMed Google Scholar

  7. Xiaoyu Zhang
    View author publications

    Search author on:PubMed Google Scholar

  8. Weihua Zhai
    View author publications

    Search author on:PubMed Google Scholar

  9. Xin Chen
    View author publications

    Search author on:PubMed Google Scholar

  10. Rongli Zhang
    View author publications

    Search author on:PubMed Google Scholar

  11. Qiaoling Ma
    View author publications

    Search author on:PubMed Google Scholar

  12. Donglin Yang
    View author publications

    Search author on:PubMed Google Scholar

  13. Jialin Wei
    View author publications

    Search author on:PubMed Google Scholar

  14. Yi He
    View author publications

    Search author on:PubMed Google Scholar

  15. Aiming Pang
    View author publications

    Search author on:PubMed Google Scholar

  16. Sizhou Feng
    View author publications

    Search author on:PubMed Google Scholar

  17. Mingzhe Han
    View author publications

    Search author on:PubMed Google Scholar

  18. Erlie Jiang
    View author publications

    Search author on:PubMed Google Scholar

Contributions

ELJ designed and supervised the study. WWG and YGC performed the research and drafted the manuscript. All other authors collected data and reviewed the manuscript.

Corresponding author

Correspondence to Erlie Jiang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, W., Cao, Y., Liu, J. et al. Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study. Bone Marrow Transplant 58, 1163–1166 (2023). https://doi.org/10.1038/s41409-023-02045-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41409-023-02045-w

This article is cited by

Search

Advanced search

Quick links